Eucalyptus (Eucalyptus globulus)

Eucalyptus globulus contains eucalyptol (1,8-cineole) as its primary bioactive compound, comprising 70-85% of the essential oil. The compound demonstrates antimicrobial properties by disrupting bacterial cell membranes and inhibiting biofilm formation.

Origin & History

Eucalyptus globulus, a species from the Myrtaceae family, is native to Australia and widely cultivated globally. The essential oil is extracted from its leaves via hydrodistillation, yielding between 2.1-2.64% oil.

Historical & Cultural Context

The dossier does not provide specific details on historical or traditional medicinal uses of Eucalyptus globulus. Its traditional use in Australian medicine is implied but not documented.

Health Benefits

• Potential inhibition of Pseudomonas fluorescens biofilms, based on in vitro studies (Preliminary evidence).

How It Works

Eucalyptol (1,8-cineole) disrupts bacterial cell membrane integrity by altering membrane fluidity and permeability. The compound interferes with quorum sensing mechanisms that regulate biofilm formation, particularly targeting Pseudomonas species. Eucalyptol also modulates inflammatory pathways by inhibiting nuclear factor-kappa B (NF-κB) activation and reducing pro-inflammatory cytokine production.

Scientific Research

There are no human clinical trials, RCTs, or meta-analyses available for Eucalyptus globulus. Current evidence is based on in vitro studies, lacking detailed human study data and PubMed PMIDs.

Clinical Summary

Current evidence is limited primarily to in vitro studies demonstrating eucalyptus oil's ability to inhibit Pseudomonas fluorescens biofilm formation. Laboratory studies show minimum inhibitory concentrations ranging from 0.25-2% for various bacterial strains. No large-scale human clinical trials have been conducted specifically for Eucalyptus globulus supplementation. The existing research represents preliminary evidence requiring further clinical validation in human subjects.

Nutritional Profile

Eucalyptus globulus leaves and derived products contain a distinctive profile dominated by volatile and bioactive compounds rather than conventional macronutrients. Key bioactive: 1,8-cineole (eucalyptol) is the primary constituent, comprising 60–85% of the essential oil by weight, with concentrations of approximately 20–30 mg/g in dried leaf material. Flavonoids present include quercetin, rutin, and hyperoside at approximately 5–15 mg/g dry weight total. Tannins (ellagitannins and condensed tannins) contribute 5–12% of dry leaf weight. Phenolic acids include gallic acid, caffeic acid, and chlorogenic acid at 1–8 mg/g dry weight. Terpenoids beyond eucalyptol include alpha-pinene (~2–5% of essential oil), limonene (~1–3%), and globulol (~1–3%). Macronutrient profile of dried leaf: crude fiber 15–25% dry weight, crude protein 5–10% dry weight (limited digestibility), crude fat 2–5% dry weight (largely essential oil fraction). Minerals detected: potassium (~8–12 mg/g dry weight), calcium (~10–18 mg/g dry weight), magnesium (~2–4 mg/g dry weight), iron (~0.1–0.3 mg/g dry weight). Vitamin E (tocopherols) present at trace levels (~0.1–0.5 mg/g). Bioavailability note: eucalyptol is highly bioavailable via inhalation and oral routes due to its lipophilic nature; polyphenol bioavailability is moderate and subject to gut microbial metabolism; the leaf is not consumed directly as food in standard diets but used medicinally as tea, tincture, or essential oil. Essential oil is toxic if ingested undiluted. Data is most robust for essential oil composition; mineral and polyphenol data reflects dried leaf studies of variable geographic origin.

Preparation & Dosage

No clinically studied dosage ranges for extracts, powders, or standardized forms are reported. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Tea tree oil, lavender oil, peppermint oil

Safety & Interactions

Eucalyptus oil is generally safe when used appropriately but can cause nausea, vomiting, and diarrhea in high doses exceeding 3.5ml. Internal use may interact with medications metabolized by cytochrome P450 enzymes, potentially altering drug clearance rates. Contraindicated in children under 2 years due to risk of respiratory depression and seizures. Pregnant and breastfeeding women should avoid internal use due to insufficient safety data.